Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yisheng Bio Raises $40 Million in a Royalty-based Funding from CBC Affiliate

publication date: Mar 23, 2022

Beijing YishengBio completed a $40 million Series C round in a royalty-based transaction with R-Bridge, a division of CBC Group focused on royalty transactions. Founded in 1994, Yisheng develops products based on its PIKA immunomodulatory adjuvant for vaccines, cancer and infectious diseases. The PIKA technology increases innate and adaptive immune responses via the TLR3, RIG-I and MDA5 pathways. The company has also developed a COVID-19 vaccine with potential for therapeutic use that is undergoing clinical trials. One year ago, YishengBio closed a $130 million B round led by OceanPine and OrbiMed. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here